Addressing the challenges of hepatitis c cure and persistent risk of hepatocellular carcinoma

Thomas F. Baumert; Yujin Hoshida

doi:10.3390/v11050441

Addressing the challenges of hepatitis c cure and persistent risk of hepatocellular carcinoma

Thomas F. Baumert, Yujin Hoshida

Research output: Contribution to journal › Editorial

5 Scopus citations

Original language	English
Article number	441
Journal	Viruses
Volume	11
Issue number	5
DOIs	https://doi.org/10.3390/v11050441
State	Published - May 2019
Externally published	Yes

Access to Document

10.3390/v11050441

Cite this

@article{74448de9d8aa40b992305b1ce91277b7,

title = "Addressing the challenges of hepatitis c cure and persistent risk of hepatocellular carcinoma",

author = "Baumert, {Thomas F.} and Yujin Hoshida",

note = "Funding Information: Funding: This work was supported by ARC (Paris) and Institut Hospitalo-Universitaire (Strasbourg; TheraHCC IHUARC IHU201301187 to Thomas F. Baumert), Foundation of the University of Strasbourg and Roche Institute (HEPKIN to Thomas F. Baumert and Yujin Hoshida), Agence Nationale de Recherches sur le Sida et les H{\'e}patites Virales (2017/1633 to Thomas F. Baumert), U.S. Department of Defense (W81XWH-16-1-0363 to Yujin Hoshida and Thomas F. Baumert), Canc{\'e}rop{\^o}le du Grand-Est (AAP Emergence 2017 to Joachim Lupberger), National Institutes of Health (DK099558 to Yujin Hoshida), European Union{\textquoteright}s Horizon 2020 research and innovation program under grant agreement 667273 (HEPCAR to Thomas F. Baumert), European Research Council under the European Union{\textquoteright}s Horizon 2020 Research and Innovation Program under grant 671231 (HEPCIR to Thomas F. Baumert and Yujin Hoshida), LABEX ANR-10-LABX-0028_HEPSYS, PLAN CANCER 2014–2019, French National Research Agency, French National Cancer Institute, and INSERM (to Thomas F. Baumert). Funding Information: This work was supported by ARC (Paris) and Institut Hospitalo-Universitaire (Strasbourg; TheraHCC IHUARC IHU201301187 to Thomas F. Baumert), Foundation of the University of Strasbourg and Roche Institute (HEPKIN to Thomas F. Baumert and Yujin Hoshida), Agence Nationale de Recherches sur le Sida et les H{\'e}patites Virales (2017/1633 to Thomas F. Baumert), U.S. Department of Defense (W81XWH-16-1-0363 to Yujin Hoshida and Thomas F. Baumert), Canc{\'e}rop{\^o}le du Grand-Est (AAP Emergence 2017 to Joachim Lupberger), National Institutes of Health (DK099558 to Yujin Hoshida), European Union{\textquoteright}s Horizon 2020 research and innovation program under grant agreement 667273 (HEPCAR to Thomas F. Baumert), European Research Council under the European Union{\textquoteright}s Horizon 2020 Research and Innovation Program under grant 671231 (HEPCIR to Thomas F. Baumert and Yujin Hoshida), LABEX ANR-10-LABX-0028_HEPSYS, PLAN CANCER 2014–2019, French National Research Agency, French National Cancer Institute, and INSERM (to Thomas F. Baumert).",

year = "2019",

month = may,

doi = "10.3390/v11050441",

language = "English",

volume = "11",

journal = "Viruses",

issn = "1999-4915",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

TY - JOUR

T1 - Addressing the challenges of hepatitis c cure and persistent risk of hepatocellular carcinoma

AU - Baumert, Thomas F.

AU - Hoshida, Yujin

N1 - Funding Information: Funding: This work was supported by ARC (Paris) and Institut Hospitalo-Universitaire (Strasbourg; TheraHCC IHUARC IHU201301187 to Thomas F. Baumert), Foundation of the University of Strasbourg and Roche Institute (HEPKIN to Thomas F. Baumert and Yujin Hoshida), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (2017/1633 to Thomas F. Baumert), U.S. Department of Defense (W81XWH-16-1-0363 to Yujin Hoshida and Thomas F. Baumert), Cancéropôle du Grand-Est (AAP Emergence 2017 to Joachim Lupberger), National Institutes of Health (DK099558 to Yujin Hoshida), European Union’s Horizon 2020 research and innovation program under grant agreement 667273 (HEPCAR to Thomas F. Baumert), European Research Council under the European Union’s Horizon 2020 Research and Innovation Program under grant 671231 (HEPCIR to Thomas F. Baumert and Yujin Hoshida), LABEX ANR-10-LABX-0028_HEPSYS, PLAN CANCER 2014–2019, French National Research Agency, French National Cancer Institute, and INSERM (to Thomas F. Baumert). Funding Information: This work was supported by ARC (Paris) and Institut Hospitalo-Universitaire (Strasbourg; TheraHCC IHUARC IHU201301187 to Thomas F. Baumert), Foundation of the University of Strasbourg and Roche Institute (HEPKIN to Thomas F. Baumert and Yujin Hoshida), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (2017/1633 to Thomas F. Baumert), U.S. Department of Defense (W81XWH-16-1-0363 to Yujin Hoshida and Thomas F. Baumert), Cancéropôle du Grand-Est (AAP Emergence 2017 to Joachim Lupberger), National Institutes of Health (DK099558 to Yujin Hoshida), European Union’s Horizon 2020 research and innovation program under grant agreement 667273 (HEPCAR to Thomas F. Baumert), European Research Council under the European Union’s Horizon 2020 Research and Innovation Program under grant 671231 (HEPCIR to Thomas F. Baumert and Yujin Hoshida), LABEX ANR-10-LABX-0028_HEPSYS, PLAN CANCER 2014–2019, French National Research Agency, French National Cancer Institute, and INSERM (to Thomas F. Baumert).

PY - 2019/5

Y1 - 2019/5

UR - http://www.scopus.com/inward/record.url?scp=85066859354&partnerID=8YFLogxK

U2 - 10.3390/v11050441

DO - 10.3390/v11050441

M3 - Editorial

C2 - 31096600

AN - SCOPUS:85066859354

SN - 1999-4915

VL - 11

JO - Viruses

JF - Viruses

IS - 5

M1 - 441

ER -